JPRN-jRCT2071230108招募中1 期
A Phase 1b Investigator-Initiated Study of Filgotinib in Patients with Idiopathic Multicentric Castleman Disease (iMCD)
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria will be included in the study.
- •(1) Patients aged >= 18 years and < 65 years at the time of informed consent
- •(2) Patients who meet the diagnostic criteria for idiopathic multicentric Castleman disease (Designated intractable disease [Notice No. 331] enforced on April 1, 2018 by the Ministry of Health, Labour and Welfare) at the time of enrollment (patients being treated must meet the diagnostic criteria at the time of enrollment.)
- •(3) Patients with a total CHAP score (CRP, hemoglobin, albumin, ECOG PS.) of >= 2 points in total with hemoglobin or albumin >= 1 point, and CRP >= 1 point at the screening examination
- •(4) Female of childbearing potential must have a negative pregnancy test and agree to use adequate contraception during the study and for 30 days after the last dose of investigational product. Male subjects must agree to a reliable and acceptable method of contraception (use of spermicide, condom or abstinence)
排除标准
- •Subjects with any one of the following items are excluded.
- •(1) Known hypersensitivity to filgotinib maleate or history of severe allergic reaction to any drug
- •(2) Prior exposure to filgotinib
- •(3) Patients who have received tocilizumab within 28 days before enrollment. Patients on treatment with tocilizumab should discontinue at least 28 days prior to study entry.
- •(4) Patients with a history of malignancy within the last 5 years (with the exception of patients with non-melanoma skin cancer or carcinoma in situ of the cervix that has responded to treatment)
- •(5) History of lymphoproliferative disease other than iMCD, lymphoma, leukemia, myeloproliferative disease, or multiple myeloma
- •(6) Patients with autoimmune disease other than iMCD (Rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, vasculitis, IgG4-related disease, Behcet's disease, etc. (but not limited to))
- •(7) Patients who were positive for HBs antigen (Patients who are negative for HBs antigen and positive for anti-HBs antibody and/or anti-HBc antibody could participate in this study.)
- •(8) Uncontrolled infection (Tuberculosis, human immunodeficiency virus, etc. (but not limited to)). Participants with a positive QuantiFERON or IFN-gamma release assay (IGRA, T-spot etc.) at screening with no evidence of an active disease could participate in the study. However, administration of appropriate anti-tuberculosis drugs should be started before administration of investigational product.
- •(9) Has any of the following laboratory abnormalities at screening:
- •- Patients with estimated GFR<60 ml/min/1.73 m2
- •- Patients with moderate or severe hepatic impairment (equivalent to or higher than Child-Pugh class B)
- •- Patients with neutrophil count < 1000/mm3
- •- Patients with lymphocyte count < 500/mm3
- •- Hemoglobin < 8.0 g/dL
- •(10)Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype of idiopathic multicentric Castleman disease for patients with definite iMCD-TAFRO with TAFRO signs
- •(11)Patients who started glucocorticoids within 14 days before enrollment (However, topical preparations and use of glucocorticoids for the treatment of iMCD are allowed.)
- •(12)Patients who have received immunosuppressants such as rituximab, sarilumab, or cyclophosphamide, TNF-alpha inhibitors such as infliximab, etanercept, adalimumab, golimumab, certolizumab, ozolarizumab, vedolizumab, or abatacept within 28 days before enrollment
- •(13)Patients who have received immunosuppressants (tacrolimus, cyclosporine, azathioprine, mizoribine, or sirolimus), JAK inhibitors (tofacitinib, baricitinib, peficitinib, upadacitinib, ruxolitinib, abrocitinib, ritrecitinib, or delgocitinib), or carotegrast within 14 days before enrollment (Topical use of immunosuppressants is permitted. Delgocitinib is approved only as a topical agent, but its concomitant use is prohibited.).
- •(14)Patients who have received a live vaccine within 7 days before enrollment and patients who are scheduled to receive a live vaccine from the enrollment date to the end date of the study
- •(15)Patients who have participated in another clinical study or clinical research within 8 weeks before enrollment
- •(16)Patients of either sex who wish to have children
- •(17)Patients who are less than 6 months postpartum at the time of enrollment, patients who have an abortion within 6 months before enrollment, and female patients who are lac
研究者
相似试验
进行中（未招募）
不适用
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced MalignanciesAdvanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2006-006515-76-GBOncolytics Biotech Inc
已完成
4 期
A Pilot Study to Evaluate Efficacy and Safety of Fixed Dose Combination Capsules in Patients with GERD and Overlapping Symptoms of DyspepsiaCTRI/2020/09/027876Abbott India limited50
招募中
不适用
Clinical study to determine the appropriateness of a starting dose of 160 mg/day of lazertinib in patients with EGFR T790M-positive non-small cell lung cancerNeoplasmsKCT0008332Samsung Medical Center117
进行中（未招募）
1 期
Study of safety and efficacy of genome-edited hematopoietic stem and progenitor cells in sickle cell disease (SCD)EUCTR2019-003489-41-ITOVARTIS PHARMA AG30
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants With Advanced Liver DiseaseEUCTR2014-003413-28-ESJanssen-Cilag International NV110